Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: XOsDaWAY2GO who wrote (22510)	7/20/1999 9:43:00 AM
From: Eagle	Respond to of 34811

Here are some comments about HTSQ from a geneticist friend of mine. I sent him a link to their web site asking his opinion. ********** They are of course in a very hot area of genetic research. They are doing DNA sequencing by chip hybridization. This is one of the technologies that may replace current electrophoretic methods. They are using this technology to find unique rare genes (a better way to say it are gene products in very low concentrations in the cell). Rare genes would be the genes of most interest in looking at specific conditions. The cell will have an abundant supply of "housekeeping" genes, but the gene products that make the cell unique are generally low level. One thing to be aware of with this type of approach is that they make no mention of protein analysis (proteomics). They are using cDNA derived from mRNA. Some recent papers are finding that there is little correlation between protein levels and mRNA levels. I personally believe that proteomics will play a larger role in the pharmaceutical industry than current genomic methods. The reason is that the pharmaceutical industry wants drug targets (i.e., proteins). The only reason proteomics lags behind genomics is that the high-throughput tools are not as well developed (proteins are harder to work with), but that is changing. From a technology standpoint I would be looking for a company integrating proteomics and genomics.